Biomolecule imaging method using aptamer

Abstract

A composition for imaging a tumorous disease region includes a fluorescence- or radioactive isotope-labeled ERBB2 aptamer, wherein the ERBB2 aptamer labeled with a radioactive isotope or a fluorescent dye is used to image the tumorous disease region in vivo. The composition may include a labeled hybridized aptamer comprising an aptamer represented as formula 1 hybridized with a labeled-ODN represented as formula 2.

Claims

1. A composition for imaging a tumorous disease region, which includes HER2-specific ERBB2 aptamer, the composition comprising: a labeled hybridized aptamer comprising an aptamer represented as formula 1 hybridized with a labeled-ODN represented as formula 2:
R-[ERBB2 aptamer]-ODN-X  [Formula 1] where R is H, cholesterol or polyethylene glycol (PEG); ERBB2 aptamer has SEQ ID NO: 1 or SEQ ID NO: 7; ODN is oligodeoxynucleotide of SEQ ID NO: 36; and X is H, idT (inverted deoxythymidine), LNA (locked nucleic acid), 2′-methoxy nucleotide, 2′-amino nucleotide, or 2′F-nucleotide;
cODN-Y  [Formula 2] where cODN is complementary oligodeoxynucleotide of the ODN; and Y is fluorescent dye or linker-radioisotope.

2. The composition according to claim 1, wherein the radioisotope is selected from .sup.18F, .sup.32P, .sup.123I, .sup.89Zr, .sup.67Ga, .sup.201Tl and .sup.111In-111.

3. The composition according to claim 2, wherein the radioisotope is .sup.18F.

4. The composition according to claim 1, wherein the fluorescent dye is a cyanine fluorescent dye.

5. The composition according to claim 4, wherein the fluorescent dye is Cy5.

6. A method for providing cancer or cancer metastasis diagnostic information, comprising: reacting a biological sample isolated from a patient with the labeled aptamer according to claim 1; measuring a binding degree of the aptamer in the biological sample of the patient; and comparing the binding degree of the aptamer in the biological sample of the patient with the binding degree of the aptamer in a normal sample thereof.

7. The method of claim 6, wherein the aptamer includes the DNA sequence of SEQ ID NO: 36 or SEQ ID NO: 37.

8. The method of claim 6, wherein the radioisotope is selected from .sup.18F, .sup.32P, .sup.123I, .sup.89Zr, .sup.67Ga, .sup.201Tl and .sup.111In-111.

9. The method of claim 6, wherein the radioisotope is .sup.18F.

10. The method of claim 6, wherein the fluorescent dye is a cyanine fluorescent dye.

11. The method of claim 6, wherein the fluorescent dye is Cy5.

12. A method for preparing a composition for imaging a tumorous disease region, comprising: reacting a cODN with Y of Formula 2 to prepare a labeled cODN represented as formula 2, and obtaining the labeled cODN; and preparing a labeled hybridized aptamer by hybridizing an aptamer represented as formula 1 with the labeled cODN represented as formula 2:
R-[ERBB2 aptamer]-ODN-X  [Formula 1] where R is H, cholesterol or polyethylene glycol (PEG); ODN is oligodeoxynucleotide; and X is H, idT (inverted deoxythymidine), LNA (locked nucleic acid), 2′-methoxy nucleotide, 2′-amino nucleotide, or 2′F-nucleotide;
cODN-Y  [Formula 2] where cODN is complementary oligodeoxynucleotide of ODN; and Y is fluorescent dye or linker-radioisotope.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 is a schematic diagram illustrating a mechanism of radiation or fluorescence-labeled ERBB2 aptamer.

(2) FIG. 2 illustrates analyzed results of R-[ERBB2 aptamer]-X-hy(bp)-Cy5, which is a product obtained by hybridization of R-[ERBB2 aptamer]-ODN-X (R=H, cholesterol or PEG, and X=H or idT) with cODN-Cy5, using Typhoon FLA 7000 3% agarose gel.

(3) FIG. 3 illustrates results of identifying the complementary base pairing between cholesteryl-[AP001-24]-ODN-idT or cholesteryl-[AP001-24]-ODN aptamer and fluorescence-labeled cODN (cODN-Cy5), using 3% agarose gel at 50, 55 and 60° C. (black: aptamer, and red: cODN-Cy5).

(4) FIG. 4 illustrates results of identifying the complementary base pairing between cholesteryl-[AP001-24]-ODN-idT, cholesteryl-[AP001-24]-ODN, PEGylated-[AP001-25]-ODN-idT or PEGylated-[AP001-25]-ODN aptamer and fluorescence-labeled cODN (cODN-Cy5), which were heated to 95° C., using agarose gel.

(5) FIG. 5 illustrates confocal image results of KPL4, N87 and SK-BR cell lines treated with R-[ERBB2 aptamer]-X-hy(bp)-Cy5, including confocal microscopic images of [AP001-24]-hy(bp)-Cy5 and [AP001-25]-hy(bp)-Cy5 aptamer in HER2-positive cell line, in particular: (a) treatment of KPL4, HER2-positive breast cancer cell line with Cy-labeled aptamer; (b) treatment using the same aptamer in N87 cancer cell line; and (c) treatment using the same aptamer in SK-BR-3 cancer cell line (marker DAPI: blue, and Cy5-aptamer: red).

(6) FIGS. 6A and 6B illustrate results of FACS analysis of KPL4, N87 and SK-BR cell lines treated with R-[ERBB2 aptamer]-X-hy(bp)-Cy5, respectively.

(7) In this regard, Table 3 shows a hybridization structure of R-[ERBB2 aptamer]-ODN-X (R=H, cholesterol or PEG, and X=H or idT) and cODN-L-F.sup.18 (L=linker), which is represented by R-[ERBB2 aptamer]-X-hy(bp)-L-F.sup.18.

(8) FIGS. 7A and 7B illustrate results of microPET images of [AP001-24]-hy(bp)-L-F.sup.18.

(9) FIGS. 8A and 8B illustrate results of microPET images of [AP001-24]-idT-hy(bp)-L-F.sup.18.

(10) FIGS. 9A and 9B illustrate results of microPET images of cholesteryl-[AP001-24]-hy(bp)-L-F.sup.18.

(11) FIGS. 10A and 10B illustrate results of microPET images of cholesteryl-[AP001-24]-idT-hy(bp)-L-F.sup.18.

(12) FIG. 11 illustrates results of microPET images of PEGylated-[AP001-24]-hy(bp)-L-F.sup.18.

(13) FIG. 12 illustrates results of microPET images of PEGylated-[AP001-24]-idT-hy(bp)-L-F.sup.18.

(14) FIG. 13 is comparative images of [AP001-24]-hy(bp)-L-F.sup.18, [AP001-24]-idT-hy(bp)-L-F.sup.18, cholesteryl-[AP001-24]-hy(bp)-L-F.sup.18 and cholesteryl-[AP001-24]-idT-hy(bp)-L-F.sup.18 in mice having KPL4 cancer.

(15) FIG. 14 illustrates determination of a degree of HER2 expression in human breast cancer cell line by Western blot.

(16) FIGS. 15A and 15B illustrate flow cytometric analysis of breast cancer cell line using HER2 antibody and ERBB2 aptamer (AP001-25), wherein: (a) a viscosity table shows fluorescent signals from antibodies to BT474 (HER2-positive cell line) and MDA-MB231 (HER2-negative cell line), with ERBB2 aptamer (AP001-25) (red) or DNA sequence of a control group (blue); and (b) flow cytometric analysis graphs of both cell lines using the antibody, ERBB2 aptamer (AP001-25) and a negative control are included.

(17) FIGS. 16A and 16B illustrate confocal microscopic images of the selected ERBB2 aptamer (AP001-25) in HER2-positive cell line, in particular: (a) treatment of BT474, HER2 positive breast cancer cell line with FITC marker aptamer; and (b) treatment using the same ERBB2 aptamer (AP001-25) in MDA-MB231 cancer cell line (marker DAPL: blue, and FITC-ERBB2 aptamer: green).

(18) FIG. 17 illustrates in vivo PET images representing .sup.18F-labeled ERBB2 aptamer {[AP001-25]-hy(bp)-L-F.sup.18} in mice having BT474 cancer, wherein Hy(bp) indicates ODN/cODN hybridization as the hybridization (base pairing).

(19) FIG. 18 illustrates studied results of in vivo distribution of .sup.18F-labeled ERBB2 aptamer {[AP001-25]-hy(bp)-L-F.sup.18} in mice having cancer, wherein data is given for active injection per gram of tissue by a percentage (% ID/g) (Error bars, SD (N=4)).

(20) FIGS. 19A to 19C illustrate in vivo PET images representing .sup.18F-labeled ERBB2 aptamer {[AP001-25]-hy(bp)-L-F.sup.18} in mice having HER2-positive and negative cancers, respectively, in particular: (a) HER2 over-expressing BT474 cancer (left armpit); (b) HER2 negative MDA-MB231 cancer (right armpit) wherein (a) shows more increased intake than in (b); and (c) count per minute (CPM) and injection amount per gram (% ID/g) into tumor tissue are calculated with .sup.18F-labeled ERBB2 aptamer.

(21) FIG. 20 illustrates H&E and IHC staining of HER2 (original magnification 400×)

DETAILED DESCRIPTION

(22) ERBB2 aptamer specifically bound to HER2 receptor in relevant to breast cancers, which is used in the present invention, has a DNA sequence of 5′-TCAGCCGCCAGCCAGTTC-[core sequence]-GACCAGAGCACCACAGAG-3′ wherein the number ‘6’ in the core sequence or ‘n’ in the attached DNA sequence listing represents NaptyldU.

(23) TABLE-US-00001 TABLE 1 Descrip-  tion (clone number) Core sequence  1 9-ER-N- A6G66AGAG666GCC6GAG6GCC6CG6AAGGGCG6AAC A01_A05 AA (SEQ ID NO: 1)  2 9-ER-N- 6AC6GGGCCCG66AGCC6C6GGCGC6CC66CGC66G6G A02_ B05 CC (SEQ ID NO: 2)  3 9-ER-N- 66A6CAACGCAC6GAGGGCG6CAGC66C66666AGG A03_C05 (SEQ ID NO: 3)  4 9-ER-N- A6G6AGAG666GCC6GAG6GCC6CGCAAGGGCG6AAC A04_D05 AG (SEQ ID NO: 4)  5 9-ER-N- 6CC6G6CCCGG666ACACAAG66AAGGCAGCCGC6GGA A06_E05 6A (SEQ ID NO: 5)  6 9-ER-N- G6C6GAACACCGAGA66AGC6GAACGAACGG6A6GGAC B02_F05 G6 (SEQ ID NO: 6)  7 9-ER-N- 6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGCCCA B03_G05 GA (SEQ ID NO: 7)  8 9-ER-N- CGCGA66AGA6GAACGCACAA6ACCCG66C6GAG6AAA B04_H05 G6 (SEQ ID NO: 8)  9 9-ER-N- G6C6GAACACCGAGA66AGCCGAACGAACGG6A6GGAC B08_A06 G6 (SEQ ID NO: 9) 10 9-ER-N- G66AGAC6GAACGCAC6GAGGGCCGCAGCC6A6C6GAA B09_B06 GG (SEQ ID NO: 10) 11 9-ER-N- A6G66AGAG666GCC6GAG6GCC6CGCAAGGGCG6AAC B12_C06 AA (SEQ ID NO: 11) 12 9-ER-N- 6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGCCCA C02_D06 GA (SEQ ID NO: 7) 13 9-ER-N- G6C6GAGCA6CGCG666AGCCGAACGC6CGG6GAGG6A C03_E06 GA6 (SEQ ID NO: 12) 14 9-ER-N- 6CA6GGCA6G66CGA6GGAGGCC666GA66ACAGCCCA C05_F06 GA (SEQ ID NO: 13) 15 9-ER-N- C6ACACGAA6CAAC6CCCC6CCGCA6AC6GAACA6CAC C06_G06 AA (SEQ ID NO: 14) 16 9-ER-N- 66AGCAAAA6GCCA6G6GCG6CC6G6CCCGG666ACAG C08_H06 C (SEQ ID NO: 15) 17 9-ER-N- 6GA6G6CCCCAAC6CAGC6G6GAA6C6A6GCCCCCGCC C10_A07 CA (SEQ ID NO: 16) 18 9-ER-N- C6GAGCGG66AC6ACACCACCG6GAGACC66AG66ACA D01_B07 AA (SEQ ID NO: 17) 19 9-ER-N- A66AGA6GAAAGCGCA66CCAACAACAGA6AA6C6GAG D02_C07 GG (SEQ ID NO: 18) 20 9-ER-N- 6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGCCCA D03_D07 GA (SEQ ID NO: 7) 21 9-ER-N- 666GGAG6G6C66ACGG66GGAG6AA6CGAGGA6GGA6 D04_E07 GA (SEQ ID NO: 19) 22 9-ER-N- CCG66ACC6ACC6CC6CGACCG6GGG6GCCC66AG6CC D05_F07 CA (SEQ ID NO: 20) 23 9-ER-N- 6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGCCAG D06_G07 A (SEQ ID NO: 21) 24 9-ER-N- CCG66ACC6ACC6CC6CGACCG6GGG6GCC666AG6CC D07_H07 CA (SEQ ID NO: 22) 25 9-ER-N- A6G66AGAG666GCC6GAG6GCC6CGCAAGGGCG6AAC D09_A08 AA (SEQ ID NO: 23) 26 9-ER-N- 6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGCCCA D11_B08 G6 (SEQ ID NO: 24) 27 9-ER-N- CCG66ACC6ACC6CC6CGACCG6GGG6GCCC66AG6CC E02_C08 CA (SEQ ID NO: 20) 28 9-ER-N- A66AGA6GAAAGCACA66CCAACAACAGA6AA6C6GAG E04_D08 GG (SEQ ID NO: 25) 29 9-ER-N- 6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGCCCA E09_E08 GA (SEQ ID NO: 7) 30 9-ER-N- A6G66AGAG666GCC6GAG6GCG6CGCAAGGGCG6AAC E11_F08 AG (SEQ ID NO: 26) 31 9-ER-N- 6GAGAAGGGC6G6GCC66AC6CAAAA666GGGA6C6G E12_G08 AA (SEQ ID NO: 27) 32 9-ER-N- G66AGAC6GAACGCAC6GAGGGCCGCAGCC6A6C6GAA F01_H08 GG (SEQ ID NO: 10) 33 9-ER-N- G6C6GAACACCGAGA66AGCCGAACGAACGG6A6GGAC F02_A09 G6 (SEQ ID NO: 9) 34 9-ER-N- G6C6GAACACCGAGA66AGCCGAACGAACGG6A6GGAC F03_B09 G6 (SEQ ID NO: 9) 35 9-ER-N- G6C6GAACACCGAGA66AGCCGAACGAACGG6A6GGAC F04_C09 G6 (SEQ ID NO: 9) 36 9-ER-N- 6CC6GG6A6G66CGA6GGAGGCC666GA66ACAGCCCA F05_D09 GA (SEQ ID NO: 28) 37 9-ER-N- 6AGA6C6C6GA66AGG6AGAACGCCC6AC6C6AACGGC F08_E09 AG (SEQ ID NO: 29) 38 9-ER-N- 6GAGAAGGGC6G6GCC66AC6CAAAA666GGGGA6C6G F09_F09 AA (SEQ ID NO: 30) 39 9-ER-N- 6GAGAAGGGC6G6GCC66AC6CAAAA666GGGGA6C6G F11_GO9 AA (SEQ ID NO: 31) 40 9-ER-N- A66AGA6GAAAGCGCA66CCAACAACAGA6AA6C6GAG G02_H09 GG (SEQ ID NO: 18) 41 9-ER-N- G6C6GAACACCGAGA66AGCCGAACGAACGG6A6GGAC G03_A10 G6 (SEQ ID NO: 9) 42 9-ER-N- CG6CC66GG6GAG666GGG6C6GAGCAGGAGCACG6GA G04_B10 G6 (SEQ ID NO: 32) 43 9-ER-N- 6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGCCCA G08_C10 GA (SEQ ID NO: 7) 44 9-ER-N- G6C6GAACACCGAGA66AGCCGAACGAACGG6A6GGAC G09_D10 G6 (SEQ ID NO: 9) 45 9-ER-N- A66AGA6GAAAGCACA66CCAACAACAGA6AA6C6GAG H01_El0 GG (SEQ ID NO: 33) 46 9-ER-N- 6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGCCCA H02_F10 GA (SEQ ID NO: 7) 47 9-ER-N- A66AGA6GAAAGCACA66CCAACAACAGA6AA6C6GAG H03_G10 GG (SEQ ID NO: 34) 48 9-ER-N- G66AGAC6GAACGCAC6GAGGGCCGCAGCC6A6C6GAA H04_H10 GG (SEQ ID NO: 10) 49 9-ER-N- 6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGCCCA H08_A11 GA (SEQ ID NO: 7) 50 9-ER-N- A6G66AGAG6C6GCC6GAG6GCC6CGCAAGGGCG6AAC H09_B11 AG (SEQ ID NO: 35)

(24) 6=NapdU [5-(N-Naphthylcarboxyamide)-[0070] 2′-deoxyuridine]. In the present invention, HER2 aptamer labeled with a radioactive isotope (‘radioisotope’), for example, .sup.18F, .sup.32P, .sup.123I, .sup.89Zr, .sup.67Ga, .sup.201Tl and .sup.111In-111, or a fluorescent dye, for example, a cyanine fluorescent dye such as Cy3, Cy5, Cy7, etc. was utilized for in vivo imaging. In embodiments of the present invention, evaluation of target specificity for in vivo molecule imaging and potential clinical application have been performed using ERBB2 aptamer labeled with the radioisotope or fluorescent dye.

(25) ERBB2 aptamer for a human epidermal growth factor receptor 2 (HER2) was labeled with .sup.18F-fluoride isotope. In order to confirm that the aptamer entered HER2 expressed cancer cell line, the aptamer was compared with a control aptamer by flow cytometry and confocal microscope. The .sup.18F-labeled HER2-specific ERBB2 aptamer was subjected to positron tomography thus to obtain biomolecular images of the mice transplanted with BT474 or KPL4 cells over time.

(26) Hereinafter, the present invention will be described in detail.

(27) Cell Culture

(28) HER2 expressed human breast cancer cell lines, e.g., BT474, KPL4, N89 and SK-BR-3 were used for in vitro and in vivo experiments. Further, a human breast cancer cell line MDA-MB231 was used as a control group. All cell lines were purchased from ATCC and incubated and maintained in MEM medium containing 10% FBS.

(29) Cell Lysis, Western Blot

(30) In order to extract intracellular protein, a cell lysate including a protease inhibitor was incubated on ice for 30 minutes. The resulting cell lysate was purified by centrifugation at 4° C. for 20 minutes. For protein quantification, the cell lysate was quantified by Bradford method, followed by separation of 30 μg protein extract from the respective samples through electrophoresis using 10% SDS-PAGE. Then, the resulting product was transferred to a nitrocellulose membrane and subjected to photosensitization on x-ray film with ECL, using HER2 antibody and the control group, that is, a beta-action antibody as a probe.

(31) ERBB2 Aptamer Synthesis

(32) DNA sequences of HER2-(+) targeting ERBB2 aptamers are shown in Table 2 below.

(33) TABLE-US-00002 TABLE 2 Binding Molecular affinity weight Code # Sequence (DNA) [Kd] (g/mole) AP001-25 [6CC6GGCA6G66CGA6GGAGGCC666GA66ACAG 0.94 nM 14163.90 CCCAGA] AP001-24 [A6G66AGAG666GCC6GAG6GCC6CGCAAGGGCG 3.10 nM 14067.80 6AACAA] [AP001-25]-ODN [6CC6GGCA6G66CGA6GGAGGCC666GA66ACAGC 3.40 nM 18701.81 CCAGA]CAGCCACACCACCAG [AP001-24]-ODN [A6G66AGAG666GCC6GAG6GCC6CGCAAGGGCG 8.20 nM 18605.71 6AACAA]CAGCCACACCACCAG
6=NapdU [5-(N-Napthylcarboxyamide)-2′-deoxyuridine]
A=2′-deoxyAdenosine
G=2′-deoxyGuanosine
C=2′-deoxyCytidine
T=2′-deoxyThymidine (Thymidine)

(34) ##STR00001##

(35) The RBB2 aptamers, in particular, AP001-24 has a binding affinity (Kd) of 3.1 nM to a target and AP001-25 has a binding affinity of 0.9 nM.

(36) Herein, 6 denotes NapdU [5-(N-naphthylcarboxamide)-2′-deoxyuridine] represented by the following formula, A=2′-deoxyadenosine, G=2′-deoxyguanosine and C=2′-deoxycytidine.

(37) ##STR00002##

(38) For aptamer hybridization, synthesis including a fully matching sequence, that is, ODN (5′-CAGCCACACCACCAG-3′) (SEQ ID NO: 36) at 3′ in each of the ERBB2 aptamers {[AP001-24] and [AP001-25]} was performed.

(39) [AP001-24]-ODN Synthesis

(40) 5′-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-3′ {[AP001-24]-ODN} was synthesized as follows.

(41) Aptamer synthesis was performed by a solid phase synthesis process through phosphoramidite coupling reaction, and after the synthesis, the product was reacted in a t-butylamine:methanol:water (1:1:2 v/v/v) solution at 70° C. for 5 hours, thus to obtain a complete aptamer through cleavage and deprotection processes, followed by drying the same. The synthesized aptamer was isolated by HPLC [C18 column (Waters, Xbridge OST C18 10×50 mm, 260 nm] and then was subjected to measurement of a molecular weight by means of ESI MS mass spectrometer (Qtrap2000, ABI).

(42) 11.sup.th aptamer in Table 1 (SEQ ID NO: 11) corresponds to AP001-24.

(43) [AP001-25]-ODN Synthesis:

(44) 5′-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-3′ {[AP001-25]-ODN} was synthesized by the same synthesis procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(45) 12.sup.th aptamer in Table 1 (SEQ ID NO: 7) corresponds to AP001-25.

(46) In the same manner, each of aptamers, that is, CAG-3′ {each of aptamers (SEQ ID NOs: 1-35) in Table 1-ODN} was synthesized by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(47) [AP001-24]-ODN-idT Synthesis:

(48) 5′-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-idT-3′ {[AP001-24]-ODN-idT} was synthesized using idT (invert dT) CPG (Glen, 20-0302-10) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(49) [AP001-25]-ODN-idT Synthesis:

(50) 5′-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-idT-3′ {[AP001-25]-ODN-idT} was synthesized using idT CPG (Glen, 20-0302-10) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(51) Cholesteryl-[AP001-24]-ODN Synthesis:

(52) 5′-cholesteryl-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-3′ {cholesteryl-[AP001-24]-ODN} was synthesized using cholesterol-PA (Glen, 10-1976-90) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(53) Cholesteryl-[AP001-25]-ODN Synthesis:

(54) 5′-cholesteryl-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-3′ {cholesteryl-[AP001-25]-ODN} was synthesized using cholesterol-PA (Glen, 10-1976-90) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(55) Cholesteryl-[AP001-24]-ODN-idT Synthesis:

(56) 5′-cholesteryl-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-idT-3′ {cholesteryl-[AP001-24]-ODN-idT} was synthesized using idT CPG (Glen, 20-0302-10) and cholesterol-PA (Glen, 10-1976-90) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(57) Cholesteryl-[AP001-25]-ODN-idT Synthesis:

(58) 5′-cholesteryl [A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-idT-3′ {cholesteryl-[AP001-25]-ODN-idT} was synthesized using idT CPG (Glen, 20-0302-10) and cholesterol-PA (Glen, 10-1976-90) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(59) PEGylated-[AP001-24]-ODN Synthesis:

(60) 5′-PEGylated-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG′ {PEGylated-[AP001-24]-ODN} was synthesized using polyethyleneglycol 2000 CED PA (ChemGenes, CLP-2119) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(61) PEGylated-[AP001-25]-ODN Synthesis:

(62) 5′-PEGylated-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-3′ {PEGylated-[AP001-25]-ODN} was synthesized using polyethyleneglycol 2000 CED PA (ChemGenes, CLP-2119) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(63) PEGylated-[AP001-24]-ODN-idT Synthesis:

(64) 5′-PEGylated-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]-CAG CCA CAC CAC CAG-idT-3′ {PEGylated-[AP001-24]-ODN-idT} was synthesized using idT CPG (Glen, 20-0302-10) and polyethyleneglycol 2000 CED PA (ChemGenes, CLP-2119) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(65) PEGylated-[AP001-25]-ODN-idT Synthesis:

(66) 5′-PEGylated-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACA A]-CAG CCA CAC CAC CAG-3′ {PEGylated-[AP001-25]-ODN-idT} was synthesized using idT CPG (Glen, 20-0302-10) and polyethyleneglycol 2000 CED PA (ChemGenes, CLP-2119) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(67) Cy5 Conjugated cODN (Complementary Oligonucleotide)[cODN-Cy5] Synthesis:

(68) The following figure represents structures of cODN-Cy5 and cODN-L-F.sup.18 (L=linker) and synthesis thereof.

(69) ##STR00003##

(70) 5′-Cy5-[CTGGTGGTGTGGCTG]-3′ (SEQ ID NO: 37) [cODN-Cy5] was synthesized using Cy5-PA (Glen, 10-5915-10) by the same procedures as described in the above section for {[AP001-24]-ODN} synthesis.

(71) Formation of cy5-Labeled ERBB2 Aptamer

(72) Table 3 below shows a hybridization structure of R-[ERBB2 aptamer]-ODN-X (R=H, cholesterol or PEG, and X=H or idT) and cODN-Cy5, which is represented by [ERBB2 aptamer]-X-hy(bp)-Cy5.

(73) TABLE-US-00003 TABLE 3 R-[ERBB2 aptamer]- X-hy(bp)-Cy5 Hybridizatin Sequence R-[ERBB2 aptamer]-X-hy(bp)-Cy5 [AP001-25]-hy(bp)- 3′-GTC CGT GTG GTG GTC-Cy5-5′ Cy5 5′-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-3′ [AP001-25]-idT-hy(bp)- 3′-GTC CGT GTG GTG GTC-Cy5-5′ Cy5 5′-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-idT-3′ Cholesteryl-[AP001-25]- 3′-GTC CGT GTG GTG GTC-Cy5-5′ hy(bp)-Cy5 5′-Chol-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-3′ Cholesteryl-[AP001-25]- 3′-GTC CGT GTG GTG GTC-Cy5-5′ idT-hy(bp)-Cy5 5′-Chol-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-idT-3′ PEGylated-[AP001-25]- 3′-GTC CGT GTG GTG GTC-Cy5-5′ hy(bp)-Cy5 5′-PEG-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-3′ PEGylated-[AP001-25]- 3′-GTC CGT GTG GTG GTC-Cy5-5′ idT-hy(bp)-Cy5 5′-PEG-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-idT-3′ [AP001-24]-hy(bp)- 3′-GTC CGT GTG GTG GTC-Cy5-5′ Cy5 5′-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-3′ [AP001-24]-idT-hy(bp)- 3′-GTC CGT GTG GTG GTC-Cy5-5′ Cy5 5′-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-idT-3′ Cholesteryl-[AP001-24]- 3′-GTC CGT GTG GTG GTC-Cy5-5′ hy(bp)-Cy5 5′-Chol-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-3′ Cholesteryl-[AP001-24]- 3′-GTC CGT GTG GTG GTC-Cy5-5′ idT-hy(bp)-Cy5 5′-Chol-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-idT-3′ PEGylated-[AP001-24]- 3′-GTC CGT GTG GTG GTC-Cy5-5′ hy(bp)-Cy5 5′-PEG-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-3′ PEGylated-[AP001-24]- 3′-GTC CGT GTG GTG GTC-Cy5-5′ idT-hy(bp)-Cy5 5′-PEG-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-idT-3′

(74) The Cy5-labeled ERBB2 aptamer, that is, {R-[ERBB2 aptamer]-X-hy(bp)-Cy5} was prepared in the following manner.

(75) First, cODN-Cy5 and [ERBB2 aptamer]-ODN in equal moles were put in an annealing buffer (PBS). Herein, a concentration of MgCl.sub.2 was controlled to reach a final concentration of 10 mM. This reaction product was left at 95° C. for 5 minutes, and then slowly cooled at room temperature. Hybridization efficiency of cODN-Cy5 and [ERBB2 aptamer]-ODN was assessed by electrophoresis (Typhoon FLA 7000 3% agarose gel analysis) and HPLC (XBridge OST analytical column (2.5 μm, 4.6×50 mm, Waters, 254 nm, 0.1M TEAA/acetonitrile). FIG. 2 shows analyzed results of R-[ERBB2 aptamer]-X-hy(bp)-Cy5 as a resulting product of hybridization of [ERBB2 aptamer]-ODN-X (R=H, cholesterol or PEG, and X=OH or idT) and cODN-Cy5, using Typhoon FLA 7000 3% agarose gel.

(76) Complementary base pairing between a synthetic oligonucleotide labeled with a fluorescent dye, that is, Cy5 (cODN-Cy5), and [ERBB2 aptamer]-ODN, was assessed. After mixing cholesteryl-[AP001-24]-ODN-idT or cholesteryl-[AP001-24]-ODN and cODN-Cy5 in 1:1 ratio, a temperature was maintained so that these components are bound together at 55, 60 and 65° C. In order to confirm the binding, electrophoresis was conducted in 3% agarose gel, followed by fluorescent imaging Cy5 through FLA 5000. Then, the entire aptamer was stained with EtBr and was subjected to UV imaging. The results are shown in FIG. 3. In order to compare the complementary base pairing between cholesteryl-[AP001-24]-ODN-idT, cholesteryl-[AP001-24]-ODN, PEGylated-[AP001-25]-ODN-idT or PEGylated-[AP001-25]-ODN and cODN-Cy5, each of these aptamers was mixed with cODN-Cy5 in 1:1 ratio and heated at 95° C. for 5 minutes to bind together, followed by assessment of the binding in the same manner as described above. The complementary base pairings between cholesteryl-[AP001-24]-ODN-idT, cholesteryl-[AP001-24]-ODN, PEGylated-[AP001-25]-ODN-idT or PEGylated-[AP001-25]-ODN and cODN-Cy5 with or without heating at 95° C., were determined and compared to each other. The comparison results are show in FIG. 4.

(77) Formation of F.sup.18 Radioisotope-Labeled cODN (Complementary Oligonucleotide) [cODN-L-F.sup.18]

(78) Synthesis of .sup.18F-labeled cODN was performed on the basis of the process already reported in the art (see reference 24). After generating no-carrier-added 18F-fluoride ions in a synthesis device (Tracerlab FXFN, GE Healthcare, Milwaukee, Wis., USA) and reacting the same with mesylate (at 100° C. for 10 minutes), .sup.18F-fluoro-PEG-azide (18F-FPA) was purified by using HPLC. After adding 1M N,N-disopropyl ethylamine in acetonitrile (10 mL) and 100 mM copper iodide (I) in acetonitrile (20 mL) to 5′-hexynyl complementary oligonucleotide (5′-hex-cODN; 200 mg), 18F-FPA (750e 1100 MBq) was further added thereto, followed by click chemistry reaction (at 70° C. for 20 minutes). The synthesized .sup.18F-labeled cODN (cODN-L-F.sup.18) was purified by using HPLC H (Xbridge OST C18 10×50 mm, an eluent of acetonitrile/0.1M TEAA in 5:95 to 95:5 over 20 minutes, flow rate: 5 mL/min, and UV (254 nm)).

(79) Formation of F.sup.18 Radioisotope-Labeled ERBB2 Aptamer {R-[ERBB2 Aptamer]-X-hy(bp)-L-F.sup.18]

(80) Table 4 below shows a hybridization structure of R-[ERBB2 aptamer]-ODN-X (R=H, cholesterol or PEG, and X=OH or idT) and cODN-L-F.sup.18 (L=lnker), which is represented by [ERBB2 aptamer]-X-hy(bp)-L-F.sup.18.

(81) TABLE-US-00004 TABLE 4 R-[ERBB2 aptamer]- X-hy(bp)-Cy5 Hybridizatin Sequence R-[ERBB2 aptamer]-X-hy(bp)-Cy5 [AP001-25]-hy(bp)- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ L-F.sup.18 5′-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-3′ [AP001-25]-idT-hy(bp)- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ L-F.sup.18 5′-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-idT-3′ Cholesteryl-[AP001-25]- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ hy(bp)-L-F.sup.18 5′-Chol-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-3′ Cholesteryl-[AP001-25]- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ idT-hy(bp)-L-F.sup.18 5′-Chol-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-idT-3′ PEGylated-[AP001-25]- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ hy(bp)-L-F.sup.18 5′-PEG-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-3′ PEGylated-[AP001-25]- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ idT-hy(bp)-L-F.sup.18 5′-PEG-[6CC 6GG CA6 G66 CGA 6GG AGG CC6 66G A66 ACA GCC CAG A]- CAG CCA CAC CAC CAG-idT-3′ [AP001-24]-hy(bp)- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ L-F.sup.18 5′-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-3′ [AP001-24]-idT-hy(bp)- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ L-F.sup.18 5′-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-idT-3′ Cholesteryl-[AP001-24]- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ hy(bp)-L-F.sup.18 5′-Chol-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-3′ Cholesteryl-[AP001-24]- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ idT-hy(bp)-L-F.sup.18 5′-Chol-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-idT-3′ PEGylated-[AP001-24]- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ hy(bp)-L-F.sup.18 5′-PEG-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-3′ PEGylated-[AP001-24]- 3′-GTC CGT GTG GTG GTC-L-F.sup.18-5′ idT-hy(bp)-L-F.sup.18 5′-PEG-[A6G 66A GAG 666 GCC 6GA G6G CC6 CGC AAG GGC G6A ACAA]- CAG CCA CAC CAC CAG-idT-3′

(82) F.sup.18 radioisotope-labeled ERBB2 aptamer, {R-[ERBB2 aptamer]-X-hy(bp)-L-F.sup.18} was prepared in the following manner.

(83) First, cODN-L-F.sup.18 and [ERBB2 aptamer]-ODN in equal moles were put in an annealing buffer (PBS). Herein, a concentration of MgCl.sub.2 was controlled to reach a final concentration of 10 mM. This reaction product was left at 95° C. for 5 minutes, and then slowly cooled at room temperature. Hybridization efficiency of cODN-L-F.sup.18 and [ERBB2 aptamer]-ODN was assessed by using HPLC (XBridge OST analytical column (2.5 μm, 4.6×50 mm, Waters, 254 nm, 0.1M TEAA/acetonitrile). These products were combined at a hybridization rate of 98% or more.

(84) Confocal Microscope

(85) BT474, KPL4, N87, SK-BR-3 and MDA-MB231 cell lines were dispensed on a coverslip and incubated overnight. When about 80% of the cell lines were grown, the grown cells were carefully washed and incubated by treatment using fluorescence-labeled ERBB2 aptamer {R-[ERBB2 aptamer]-hy(bp)-Cy5} at a concentration of 250 mM. After culture, the product was carefully washed, followed by loading a culture medium containing DAPI on a slide. Then, florescence thereof was observed by an LSM 700 confocal microscope. Microscope setting was performed as follows: a 488 laser was used for FITC observation; excitation and emission were observed using BP490-555; a 639 laser was used for Texas red; and emission was observed using an LP640 filter.

(86) In the same manner as the previous experiments, ERBB2 over-expressing breast cancer cell lines, e.g., KPL4, N87 and SK-BR-3 were dispensed on a coverslip and incubated overnight. When about 80% of the cell lines were grown, the grown cells were carefully washed and incubated by treatment using a sample prepared of Cy5 fluorescence-labeled ODN bound to ERBB2 aptamer using complementary base pairing. After culture, the product was carefully washed, followed by loading a culture medium containing DAPI on a slide. Then, florescence was observed by an LSM 700 confocal microscope.

(87) The observed results are shown in FIG. 5.

(88) Flow Cytometry

(89) Specificity of ERBB2 aptamer was verified by a fluorescence activated cell separation method using a flow cytometry system (BD Biosciences). Appropriate numbers of BT474, KPL4, N87, SK-BR-3 or MDA-MB231 cancer cell lines were sub-cultured on a Petri-dish to grow the same to about 80%. The grown cells were treated with trypsin and washed with PBS, followed by binding fluorescence-labeled ODN to ERBB2 aptamer through a complementary base generated according to a temperature. The cells were treated with the binding-completed sample. Both of the ERBB2 aptamer {R-[ERBB2 aptamer]-hy(bp)-Cy5} and the control group, that is, 1% FES containing antibody were treated at 4° C. for 30 minutes, respectively. The completely treated sample was washed, followed by measurement and analysis of the bound ERBB2 aptamer by a fluorescence activated cell separation method.

(90) Results of the above measurement and analysis are shown in FIGS. 6A to 6B.

(91) In Vivo Experiments

(92) 17ββ-estradiol pellets were subcutaneously implanted into a side region of the neck of a 4 week-old Balb/c nude mouse so that estrogen is released in a sufficient amount to potentially induce a cancer. A few days later, BT474 or KPL4 human breast cancer cell line was subcutaneously implanted in 7×10.sup.6 cells per mouse. After allowing the cancer to develop for 3 weeks, cancer growth was measured using a caliper.

(93) Into the right shoulder of Balb/C nude mouse, KPL4 cells as the human breast cancer cell line were subcutaneously implanted in 1×10.sup.5 cells per mouse. Thereafter, occurrence of cancer was induced.

(94) PET Imaging of F.sup.18 Radioisotope-Labeled ERBB2 Aptamer

(95) F.sup.18 radioisotope-labeled ERBB2 aptamer was injected to a mouse, and after 60 minutes, static images were obtained by Inveron microPET scanner (Siemens, Knoxville, Tenn., USA) for 10 minutes. For F.sup.18 radioisotope-labeled ERBB2 aptamer injection, the mouse was breathing anesthetized with 2% Isoflurane, followed by 7.4 MBq of F.sup.18 radioisotope-labeled ERBB2 aptamer injection into a tail vein. The obtained listmode data is converted into synogram and re-configured by 3D Ordered Subset Expectation Maximization (OSEM) algorithm, followed by assessment using ASIpro (Concord Microsystems Inc., Knoxville, Tenn.).

(96) After intravenous injection of F.sup.18 radioisotope-labeled ERBB2 aptamer to a mouse having tumor grown by injection of human breast tumor cells, PET was executed using inveon PET of Siemens (Knoxville, Tenn.). The injected amount was 13.7±1.1 MBq (370±30 uCi), and dynamic PET study was implemented for 30 minutes according to ten 1-minute image and four 5-minute image protocols. These two stationary studies were conducted for 10, 60, 90 and 120 minutes, respectively, after the injection. Partial quantification of PET signals was executed by AMIDE software. Images were practically gained by false-color-scale in proportional to the tissue concentration (% ID/g) of a positron labeling probe. Red represents the highest concentration, while yellow, green and blue correspond to gradually lower concentrations.

(97) PET images are shown in FIGS. 7A to 13.

(98) Result

(99) Verification of HER2 Expression and Affinity of Aptamer to Target Tumor Cell

(100) Western blot and flow cytometry were performed to investigate HER2 expression in a breast cancer cell line, BT474. Through western blot analysis, over-expression in BT474 as well as SKBR3 cell line known to over-express HER2 due to gene amplification was confirmed. Further, it was found that no signal is detected at the corresponding site in a negative control cell line, MDA-MB231 (FIG. 14).

(101) As shown in FIGS. 15A and 15B, it is proven that HER2 antibody is very specifically bound to HER2-positive BT474 cell line using the flow cytometry. As compared to the antibody, it can be seen that ERBB2 aptamer is very weak in MDA-MB231 cell line, whereas in BT474 cell line it is strongly bound thereto. Moreover, binding of the aptamer to any cell line could not be seen in random oligonucleotides. These results suggest that ERBB2 aptamer is preferentially bound to HER2-positive cell lines, and such binding may be possible by recognizing HER2 structure on the surface of the cell line. In the same manner, it was observed that KPL4 as a breast cancer cell line is strongly bound to SK-BR-3 cell line fluorescence-labeled aptamer.

(102) Confocal Microscope Analysis

(103) Binding of ERBB2 aptamer to cells was further assessed by a confocal microscope (FIGS. 16A and 16B). BT474 HER2-positive breast cancer cell line was treated with the aptamer. Since ERBB2 aptamer was fluorescence-labeled, fluorescence was observed on the surface of the cell, and HER2 structure present on the cell surface was identified. Fluorescence exhibited by the aptamer was observed along a cellular membrane, while MDA-MB231 cell line as a negative control group did not indicate any fluorescent signal and thus was determined not to include HER2. Accordingly, it was observed that ERBB2 aptamer could be bound to HER2-positive breast cancer cell line, but is minimally bound to HER2-negative cells. After treatment of the breast cancer cell lines KPL4, N87 and SK-BR-3 with ERBB2 aptamers {[AP001-24] and [AP001-25]}, which form complementary base pairings along with fluorescence-labeled ODN, fluorescence observation was performed using a confocal microscope by the same procedures as conducted in the above experiments. It was found that the above both types of ERBB2 aptamers were well bound to the breast cancer cell lines, wherein [AP001-24] showed fluorescence on the cell surface along the cellular membrane, while [AP001-25] showed fluorescence even inside the cell.

(104) In Vivo PET Imaging, In Vivo Distribution, Immuno-Histochemistry

(105) In vivo bio-molecular images of mice having BT474 or KPL4 cancer were given over time according to animal micro-PET. Referring to FIG. 17, it was observed that intake of 18F-labeled HER2-specific ERBB2 aptamer is significantly increased in tumor tissues present in the left armpit of a mouse. In images taken for 120 minutes, the cancer was distinctly labeled by ERBB2 aptamer in horizontal images and coronal images. Physiological intake clearly appearing in the intestine and bladder may reflect these organs as two major discharge routes of radiation medicine.

(106) In vivo distribution was verified in the mice having cancer, 1 hour after injection of .sup.18F-labeled ERBB2 aptamer. After sacrificing the animal, radiation levels in separate tissues including the cancer were measured by a gamma counter, and then expressed in % ID/g (FIG. 18) Measured results are also shown in Table 5 below.

(107) TABLE-US-00005 TABLE 5 Organs % ID/g (±SD) Blood 0.60 ± 0.06 Heart 0.43 ± 0.03 Liver 1.11 ± 0.11 Lung 0.47 ± 0.06 Spleen 0.44 ± 0.03 Kidney 3.19 ± 1.02 Stomach 0.62 ± 0.13 Small Intestine 2.23 ± 0.81 Large Intestine 4.62 ± 1.09 Muscle 0.52 ± 0.09 Femur 0.65 ± 0.19 BT474 tumor 0.62 ± 0.04

(108) The intake of .sup.18F-labeled ERBB2 aptamer in the cancer was 0.62±0.04 per hour. Study on in vivo distribution demonstrated that the kidney and the intestine are two major discharge routes of .sup.18F-labeled ERBB2 aptamer.

(109) FIGS. 19A to 19C illustrate images of .sup.18F-labeled ERBb2 aptamer in mice having HER2-positive and negative cancers, respectively. HER2 over-expressing BT474 cancer shows higher isotopic intake than HER2-negative MSA-MB231 cancer by comparison. For the purpose of semi-quantification, total activity (nCi) among VOIs (voxels- or volumes-of-interest) was calculated. As a result of comparison of T/M (tumor/muscle) intake ratio between BT474 and MDA-MB231 cell lines, HER2 over-expressed in BT474 cancer showed higher T/M ratio and contrast image (FIGS. 19A to 19C). In immuno-histochemical aspects, it was confirmed that BT474 cancers excised from separate mouse groups showed high HER2 expression, whereas MDA-MB231 cells have lower HER2 expression (FIG. 20). It was observed that BT474 cancer cells (upper row) show higher staining for HER2 in a cellular membrane than MDA-MB231 cell line (lower row) by comparison.

(110) According to the present invention, HER2 targeting ERBB2 aptamer was successfully PET-imaged in vivo. The present invention is the first case to execute HER2 target PET imaging using ERBB2-specific aptamer. In mice with BT474 cancer, PET images demonstrated that ERBB2 aptamer may recognize HER2 in vivo and relatively distinctively show the cancer. Based on these results, the radio-labeled ERBB2 aptamer may be applied to targeted treatment of HER2-positive breast cancer cell line or potentially applied to determination of appropriate therapeutic methods for the same.

(111) As identified in the above embodiments, when R-[ERBB2 aptamer]-ODN-X/cODN-L-F.sup.18 (represented by R-[ERBB2 aptamer]-X-hy(bp)-L-F.sup.18 in the above description) is prepared by combining R-[ERBB2 aptamer]-ODN-X with cODN-L-F18, the aptamer chemically modified (i.e., protected) at 5′ terminal or 3′ terminal position, or both of these terminal positions, for example, from R=H (No protecting) and X=H (No protecting) to R=cholesterol or PEG (polyethyleneglycol) and X=idT (inverted deoxythymidine), LNA (locked nucleic acid), 2′-methoxy nucleotide, 2′-amino nucleotide, 2′F-nucleotide, etc., may assure better images.

(112) Since the modification due to the above compounds may improve effects of increasing t.sub.1/2 (half-life) blood clearance, that is, increase in vivo half-life in blood, ERBB2 aptamer having a radioisotope bound thereto is increasingly bound to a tumor thus to improve imaging efficiency [as compared to t.sub.1/2=10 minutes when R=H and X=H, t.sub.1/2 increases to 1 hour if R and X are protected and modified, thereby demonstrating better images].

REFERENCES

(113) 1. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990; 249: 505-10. 2. Ellington A D, Szostak J W. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346: 818-22. 3. Stoltenburg R, Reinemann C, Strehlitz B. SELEX—a (r) evolutionary method to generate high-affinity nucleic acid ligands. Biomolecular engineering. 2007; 24: 381-403. 4. Spiridonova V A, Kopylov A M. DNA aptamers as radically new recognition elements for biosensors. Biochemistry Biokhimiia. 2002; 67: 706-9. 5. Jayasena S D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clinical chemistry. 1999; 45: 1628-50. 6. Bock L C, Griffin L C, Latham J A, Vermaas E H, Toole J J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature. 1992; 355 (6360): 564-6. 7. Bates P J, Laber D A, Miller D M, Thomas S D, Trent J O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Experimental and molecular pathology. 2009; 86: 151-64. 8. Lupold S E, Hicke B J, Lin Y, Coffey D S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer research. 2002; 62: 4029-33. 9. Daniels D A, Chen H, Hicke B J, Swiderek K M, Gold L. A tenaascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 15416-21. 10. James W. Aptamers in the virologists' toolkit. The Journal of general virology. 2007; 88 (Pt 2): 351-64. 11. Doggrell S A. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert opinion on pharmacotherapy. 2005; 6: 1421-3. 12. Dausse E, Da Rocha Gomes S, Toulme J J. aptamers: a new class of oligonucleotides in the drug discovery pipeline? Current opinion in pharmacology. 2009; 9: 602-7. 13. Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemotherapy research and practice. 2012; 2012: 743193. 14. Burstein H J. The distinctive nature of HER2-positive breast cancers. The New England journal of medicine. 2005; 353: 1652-4. 15. Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Advances in experimental medicine and biology. 2007; 608: 119-29. 16. Baselga J, Swain S M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature reviews Cancer. 2009; 9: 463-75. 17. Dastjerdi K, Tabar G H, Dehghani H, Haghparast A. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnology and applied biochemistry. 2011; 58: 226-30. 18. Liu Z, Duan J H, Song Y M, Ma J, Wang F D, Lu X et al. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. Journal of translational medicine. 2012; 10: 148. 19. Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110: 8170-5. 20. Mahlknecht G, Sela M, Yarden Y. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy. Methods in molecular biology (Clifton, N.J.). 2015; 1317: 3-15. 21. Moosavian S A, Jaafari M R, Taghdisi S M, Mosaffa F, Badiee A, Abnous K. Development of RNA aptamers as molecular probes for HER2 (+) breast cancer study using cell-SELEX. Iranian journal of basic medical sciences. 2015; 18: 576-86. 22. James M L, Gambhir S S. A molecular imaging primer: modalities, imaging agents, and applications. Physiological reviews. 2012; 92: 897-965. 23. Hicke B J, Stephens A W, Gould T, Chang Y F, Lynott C K, Heil J et al. Tumor targeting by an aptamer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2006; 47: 668-78. 24. Jacobson O, Yan X, Niu G, Weiss I D, Ma Y, Szajek L P et al. PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2015; 56: 616-21. 25. Pala K, Serwotka A, Jelen F, Jakimowicz P, Otlewski J. Tumor-specific hyperthermia with aptamer-tagged superparamagnetic nanoparticles. International journal of nanomedicine. 2014; 9: 67-76. and Lee J H, Chae Y C, Kim Y, Kang H, Im J H, Kim J I, Kim K S, Jang S K, Oh I U, Choi M J, Kang W J. “Aptamer which selectively binds to ERBB2 receptor and uses thereof” U S 2015/0005368 A1 (Jan. 1, 2015). 26. Flagothier J, Kaisin G, Mercier F, Thonon D, Teller N, Wouters J et al. Synthesis of two new alkyne-bearing linkers used for the preparation of siRNA for labeling by click chemistry with fluorine-18. Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine. 2012; 70: 1549-57. 27. Ramenda T, Steinbach J, Wuest F. 4-[18F] Fluoro-N-methyl-N-(propyl-2-yn-1-yl) benzenesulfonamide ([18F] F-SA): a versatile building block for labeling of peptides, proteins and oligonucleotides with fluorine-18 via Cu (I)-mediated click chemistry. Amino acids. 2013; 44: 1167-80. 28. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic acids research. 2003; 31 (13): 3406-15. 29. Kibbe W A. OligoCalc: an online oligonucleotide properties calculator. Nucleic acids research. 2007; 35 (Web Server issue): W43-6. 30. Tang G, Zeng W, Yu M, Kabalka G. Facile synthesis of N-succinimidyl 4-[18F] fluorobenzoate ([18F]SFB) for protein labeling. Journal of Labelled Compounds and Radiopharmaceuticals. 2008; 51: 68-71. 31. Tang G, Tang X, Wang X. A facile automated synthesis of N-succinimidyl 4-[18F] fluorobenzoate ([18F]SFB) for 18F-labeled cell-penetrating peptide as PET tracer. Journal of Labelled Compounds and Radiopharmaceuticals. 2010; 53: 543-7. 32. Scott P J H, Shao X. Fully automated, high yielding production of N-succinimidyl 4-[18F]fluorobenzoate ([18F] SFB), and its use in microwave-enhanced radiochemical coupling reactions. Journal of Labelled Compounds and Radiopharmaceuticals. 2010; 53: 586-91. 33. Kraus M H, Popescu N C, Amsbaugh S C, King C R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. The EMBO journal. 1987; 6: 605-10. 34. Varmira K, Hosseinimehr S J, Noaparast Z, Abedi S M. An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers. Journal of drug targeting. 2014; 22: 116-22. 35. Bouchard P R, Hutabarat R M, Thompson K M. Discovery and development of therapeutic aptamers. Annual review of pharmacology and toxicology. 2010; 50: 237-57. 36. Sun H, Zhu X, Lu P Y, Rosato R R, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Molecular therapy Nucleic acids. 2014; 3: e182. 37. Lao Y H, Phua K K, Leong K W. aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS nano. 2015; 9: 2235-54. 38. Sun H, Zu Y. A Highlight of Recent Advances in Aptamer Technology and Its Application. Molecules. 2015; 20: 11959-80. 39. Rosenberg J E, Bambury R M, Van Allen E M, Drabkin H A, Lara P N, Jr., Harzstark A L et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investigational new drugs. 2014; 32: 178-87. 40. Dassie J P, L I Hernandez, Thomas G S, Long M E, Rockey W M, C A Howell et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Molecular therapy: the journal of the American Society of Gene Therapy. 2014; 22: 1910-22. 41. Xu W, Siddiqui I A, Nihal M, Pilla S, Rosenthal K, Mukhtar H et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials. 2013; 34: 5244-53. 42. Lim E K, Kim B, Choi Y, Ro Y, Cho E J, Lee J H et al. Aptamer-conjugated magnetic nanoparticles enable efficient targeted detection of integrin alphavbeta3 via magnetic resonance imaging. Journal of biomedical materials research Part A. 2014; 102: 49-59. 43. Hu H, Dai A, Sun J, Li X, Gao F, Wu L et al. Aptamer-conjugated Mn3O4@SiO2 core-shell nanoprobes for targeted magnetic resonance imaging. Nanoscale. 2013; 5: 10447-54.

(114) A sequence listing electronically submitted with the present application on Oct. 25, 2019 (filing date) as an ASCII text file named 20191025_Q16819LC39_TU_SEQ, created on Oct. 24, 2019 (saved date) and having a size of 13312 bytes, is incorporated herein by reference in its entirety.